A Phase I Study of CS5007 in Participants With Advanced Solid Tumors

Exclusion Criteria

• •Has disease that is suitable for local treatment administered with curative intent.
• •Has a history of a second malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
• •Known primary central nervous system (CNS) tumor or solid tumor CNS metastasis that is symptomatic, untreated, or requires therapy.
• •Has life-threatening bleeding event or severe bleeding within 3 months prior to first dose.
• •Has uncontrolled pleural effusion, pericardial effusion, or ascites.
• •Has immune deficient disease or received systemic immunosuppressive treatment.
• •Has intestinal obstruction,or history of inflammatory bowel disease,or chronic diarrhea.
• •Has history of (non-infectious) interstitial lung disease/pneumonitis that required steroids.
• •Has active infections requiring systemic therapy.
• •Has significant cardiovascular disease or cerebrovascular accident within specified timeframes prior to first dose.
• •Insufficient washout from prior anti-tumor therapy.
• •Received live vaccine within 28 days prior to first dose.
• •History of allogeneic organ or hematopoietic stem cell transplantation.
• •History of hypersensitivity to excipients of study drug or any monoclonal antibody.
• •Any toxic effects of prior therapy unresolved to Grade ≤1.
• •Active alcohol or drug abuse.
• •Pregnant or breastfeeding women.
• •Other acute or chronic medical or psychiatric conditions that may increase risk or interfere with study results, in the investigator's judgment.